During the last session, Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s traded shares were 0.31 million, with the beta value of the company hitting 1.62. At the end of the trading day, the stock’s price was $15.71, reflecting an intraday loss of -0.95% or -$0.15. The 52-week high for the TNXP share is $672.00, that puts it down -4177.53 from that peak though still a striking 56.97% gain since the share price plummeted to a 52-week low of $6.76. The company’s market capitalization is $108.05M, and the average intraday trading volume over the past 10 days was 0.87 million shares, and the average trade volume was 1.70 million shares over the past three months.
Tonix Pharmaceuticals Holding Corp (TNXP) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. TNXP has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -3.09.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) trade information
Tonix Pharmaceuticals Holding Corp (TNXP) registered a -0.95% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.95% in intraday trading to $15.71, hitting a weekly high. The stock’s 5-day price performance is -9.19%, and it has moved by -4.61% in 30 days. Based on these gigs, the overall price performance for the year is -96.72%. The short interest in Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is 0.92 million shares and it means that shorts have 0.39 day(s) to cover.
Tonix Pharmaceuticals Holding Corp (TNXP) estimates and forecasts
In the rating firms’ projections, revenue will increase 9.97% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 2.55M as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 2.65M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 2.48M and 2.21M respectively. In this case, analysts expect current quarter sales to grow by 2.74% and then jump by 20.02% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 46.06%. While earnings are projected to return 93.27% in 2025.
TNXP Dividends
Tonix Pharmaceuticals Holding Corp is due to release its next quarterly earnings on 2025-Mar-17. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
